SCD and type 2 diabetes mellitus: Interestingly, administration of T2DM drugs functioning as the peroxisome proliferator-activated receptor-g agonist glitazone leads to increased mRNA expression and activity of scd-1 in humans (Risérus et al., 2005; Yao-Borengasser et al., 2008).